Skip to main content
Evidence Snapshot

Epidermal growth factor receptor

CHEMBL3608 SINGLE PROTEIN Mus musculus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:15Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3608
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Epidermal growth factor receptor as ChEMBL target CHEMBL3608, mapped to UniProt Q01279. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Epidermal growth factor receptor
SINGLE PROTEIN · Mus musculus
As of 2026-09-14
ChEMBL target ID
CHEMBL3608
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q01279
Epidermal growth factor receptor
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Epidermal growth factor receptor matters

As of 2026-09-14

Epidermal growth factor receptor is reviewed as Epidermal growth factor receptor (UniProt Q01279); the current evidence base includes 5 approved drugs, 125 compounds, and 50 assays, with lead potency reaching pChEMBL 8.8.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 5 approved drugs, 125 compounds, and 50 assays for this target. The dominant activity type is IC50. CHEMBL545315 is the current potency anchor at pChEMBL 8.8.

Use CHEMBL545315 as the tractability anchor when discussing potency (pChEMBL 8.8).

Activity source · ChEMBL 36 via Core Engine
5 approved pChEMBL 8.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Epidermal growth factor receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q01279, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

125
Total Compounds
50
Total Assays
5
Approved Drugs
IC50: 97.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL545315
 8.8 IC50 Clinical
No preferred name
CHEMBL2110732
 8.2 IC50 Approved
No preferred name
CHEMBL5440872
 8.1 IC50 —
No preferred name
CHEMBL3353410
 8.1 IC50 Approved
No preferred name
CHEMBL939
 7.8 IC50 Approved

Approved Drugs

Structure Compound First Approval
DACOMITINIB ANHYDROUS
CHEMBL2110732
 2018
OSIMERTINIB
CHEMBL3353410
 2015
ERLOTINIB
CHEMBL553
 2004
GEFITINIB
CHEMBL939
 2003
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:15Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3608